



Drug Name: Breo Ellipta 50/25 mcg, fluticasone furoate/vilanterol 100/25 mcg and 200/25 mcg, and fluticasone/salmeterol HFA 45/21 mcg, 115/21 mcg and 230/21 mcg,

Last Revision Date: 06/2016, 4/2020, 5/2021, 7/2021, 6/2022, 5/2023, 12/2023, 03/2024, 03/3025, 01/2026

| | |
|---------------------------------------|---|
| Required Medical Information: | The member has tried and failed a short acting/rescue albuterol inhaler, inhaled corticosteroid, or a generic/formulary no restriction ICS/LABA combination product (e.g., Wixela) within the past 90 days |
| Coverage Duration: | 12 months |
| Coding Logic for Step Therapy: | Breo Ellipta 50/25 mcg, fluticasone furoate/vilanterol 100/25 mcg and 200/25 mcg, or fluticasone/salmeterol 45/21mcg, 115/21 mcg and 230/21 mcg will pay if there is a paid claim in the PBM's system for a short acting albuterol inhaler, inhaled corticosteroid, or a generic/formulary no restriction ICS/LABA combination product within the past 365 days |